Cyberlux : CYBL OTC Attorney Opinion Letter for Amended 03-31-2022 Quarterly Report Final 06.15.2022

WATTS LAW, PLLC

732 Ninth Street | 919-491-0560 | [e-mail]

June 15, 202 2

OTC Disclosure and News Service

304 Hudson Street, Second Floor

New York, New York 10013

RE: Cyberlux Corporation Quarterly Report for the Period Ending March 31, 2022

Dear Sir or Madam:

I have acted as counsel to Cyberlux Corporation, a Nevada Corporation (the "Issuer"), on specific securities and

corporate issues and have been retained for the purpose of reviewing the current information supplied by the Issuer, specifically with respect to the Issuer's amended quarterly financials for the quarter ended March 31, 2022 (the "Report") publicly disclosed by the Issuer and published in the OTC Disclosure and News Service. This opinion is solely for the information of the OTC Disclosure and News Service, which is entitled to rely on this

letter in determining whether the Issuer has made adequate information publicly available within the meaning of Rule 144(c)(2) of the Securities Act of 1933, as amended (the "Act"). The amended financials for the quarter ending March 31, 2022 were initially filed with the OTC Disclosure and News Service on www.OTCmarkets.comand posted on June 15, 2022.

This opinion is solely for the information of the OTC Disclosure and News Service, which is entitled to rely on this letter in determining whether the Issuer has made adequate information publicly available within the meaning of Rule 144(c)(2) of the Securities Act of 1933, as amended (the "Act"). I hereby consent to having this letter posted by the Issuer, and to have t published, accompanying its disclosure in the OTC Disclosure and News Service.

I am a United States resident and currently represent the Issuer. This opinion is based on my knowledge of the law and facts as of the date hereof. I have examined such corporate records and other documents and such questions of law as deemed appropriate for the purpose of rendering this opinion. I am licensed to practice law in the United States in the State of North Carolina and I am permitted to practice before the Securities and Exchange Commission (the "SEC"). I have not been prohibited from practicing law at any point in my more than 30 year career and have not been prohibited from practicing before the SEC. I am a stockholder in the Issuer but will not receive any shares of the Issuer for providing this letter.

As to matters of fact upon which I have relied and obtained from officers and directors of the Issuer and other sources, I have believed such sources to be reliable. I have examined such corporate records and other documents and asked such questions as I deemed necessary or appropriate for purposes of rendering this letter. Based upon such investigation, to the best of my knowledge, neither the Issuer, its officers and directors, any holder of 5% or more of the securities of the Issuer, nor counsel for the Issuer, is currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.

For the purposes of rendering this opinion, I have assumed that no person or entity has engaged in fraud or misrepresentation regarding the inducement relating to execution or delivery of the documents reviewed. Furthermore, I express no opinion as to the validity of any of the assumptions, form or content of any financial or statistical data contained therein.

Regarding the Issuer's common stock, par value $0.001 (the "Securities"), based on the examination and inquiry set forth above, I am of the opinion that the Report, as published on the OTC Disclosure and News Service on the dates described above, (the "Information") (i) constitutes "adequate current public information" concerning the Securities of the Issuer and "is available" within the meaning of Rule 144( c)(2) under the Securities Act, (ii) includes all the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Act, (iii) complies as to form with the Pink OTC Marker Guidelines for Providing Adequate Current Information, which are located on the Internet at www.pinksheets.com, and (iv) has been posted in the OTC Disclosure and News Service.

The Issuer's unaudited amended financial statements were prepared by and under the direction of David D. Downing, the Issuer's Chief Financial Officer. The Issuer has represented that the unaudited financial statements were prepared in accordance with generally accepted accounting principles.

The Issuer's transfer agent is Standard Registrar & Transfer Company, Inc., and to the best of my knowledge, it is registered with the SEC. I have reviewed a copy of the stockholder list prepared by the transfer agent as of March 31, 2022 to confirm that the number of outstanding shares is consistent with the Issuer's information.

I have (i) personally met with the Issuer's management and a majority of its directors, (ii) reviewed the Information published by the Issuer on the OTC Disclosure and News Service, and (iii) discussed the Information with management and a majority of the directors of the Issuer.

This opinion is solely for the information of the addressee and the other parties specifically identified in the second paragraph hereof, and is not to be quoted in whole or in part or otherwise referred to, nor is it to be filed with any governmental agency or other person without my prior written consent. Other than the addressee hereof and other such parties, no one is entitled to rely on this opinion. This opinion is based on my knowledge of the law and facts as of the date hereof. I assume no duty to communicate with you with respect to any matter which comes to my attention hereafter.

Sincerely,

Watts Law, PLLC

Managing Member

2